Company Name
Sichuan Gowell Pharmaceutical Co.,Ltd.
Year of Establishment
2011
Company Introduction
Sichuan Guowei Pharmaceutical Co., Ltd. was established in 2011 with a registered capital of 50 million yuan. It is a national high-tech enterprise specializing in the research, development, production and sales of high-end chemical generic drugs, OMEGA-3 fish oil unsaturated fatty acid series drugs and health foods, and peptide drugs. The products are mainly concentrated in the cardiovascular system, urinary and renal system, digestive system, and anti-infection system. The company currently has more than 270 employees and a total area of 170 acres. It has an annual production capacity of 100 tons of chemical raw materials, 500 million oral solid preparations/tablets, 500 million soft capsules, and more than 300 tons of high-purity OMEGA-3 fish oil.
The company has built a provincial enterprise technology center, covering five major R&D technology platforms for first-copy and special small molecule drugs, peptide drugs, natural multi-component drugs, new preparations and innovative drugs. At present, it has obtained 9 pharmaceutical preparations, 14 raw materials and 3 health food production approvals, and has 4 domestic first-copy listed products, 4 national centralized procurement winning products, 23 authorized patents, and obtained 1 national major new drug creation project and nearly 20 provincial and municipal science and technology project support.
Up to now, the company has won many titles such as Sichuan Province Science and Technology Achievement Transformation Demonstration Enterprise, Sichuan Province Gazelle Enterprise, Sichuan Province Technological Innovation Demonstration Enterprise, and Top 100 Comprehensive Strength Industrial Enterprises in China's Chemical Pharmaceutical Industry. It has successfully solved many original research patent obstacles, achieved continuous launch of new products, driven the localization process of patented drugs, and promoted the development of my country's pharmaceutical industry.
Main Competitive Advantages
Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service,
Milestone
•2005: Guowei Pharmaceutical was established;
•2008: Guowei Pharmaceutical's star product "Nalmefene Hydrochloride Injection (Lemeng)" was launched;
•2010: Guowei Pharmaceutical R&D Center was established, opening the road to independent research and development;
•2011: Chengdu Guowei Biomedicine was established, and a wholly-owned subsidiary Sichuan Guowei Pharmaceutical was established;
•2012: Specialized workshops were built and drug production licenses were obtained;
•2014: Moxifloxacin hydrochloride API and injection production approval was obtained; first in Domestically, 90% omega-3 ethyl ester high-purity deep-sea fish oil soft capsules were launched, and Ocuien was listed;
•2015: Chengdu Guowei Biological passed the "National High-tech Enterprise" certification;
•2017: Sichuan Guowei passed the "National High-tech Enterprise" certification;
•2018: Obtained the approval documents for moxifloxacin hydrochloride tablets (second copy) and moxifloxacin hydrochloride sodium chloride injection (first copy), becoming a domestic manufacturer with all dosage forms of moxifloxacin; obtained the production approval document for solifenacin succinate tablets (first copy).
•2019: Obtained the production approval document for linena glucose injection;
•2020: Obtained the production approval document for dutasteride soft capsules, paricalcitol injection, and celecoxib capsules;
•2021: Obtained the production approval document for ω-3 fatty acid ethyl ester 90 soft capsules and calcitriol soft capsules.
•2022: Obtained the production approval document for mirabegron sustained-release tablets.
•2023: Obtain production approval for idecalcitol and eicosapent ethyl.